Viewing Study NCT01107782



Ignite Creation Date: 2024-05-05 @ 10:26 PM
Last Modification Date: 2024-10-26 @ 10:18 AM
Study NCT ID: NCT01107782
Status: UNKNOWN
Last Update Posted: 2011-02-23
First Post: 2010-01-13

Brief Title: Sildenafil and Uteroplacental Perfusion
Sponsor: Tehran University of Medical Sciences
Organization: Tehran University of Medical Sciences

Study Overview

Official Title: Phase 2 Study of Fetal Growth Retardation Treatment by Sildenafil
Status: UNKNOWN
Status Verified Date: 2011-02
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to determine whether sildenafil is effective and safe in the treatment of fetal growth restriction
Detailed Description: Fetal growth retardation affects up to 8 of all pregnancies and has massive short term increased fetal morbidity and mortality and long-term increased incidence of cardiovascular disorders in adulthood health implications

Doppler waveform analysis of these pregnancies suggests compromised uteroplacental circulation and placental hypoperfusion

Our aim is to assess if sildenafil citrate could improve vasodilatation in FGR pregnancies

Sildenafil citrate may offer a potential therapeutic strategy to improve uteroplacental perfusion in FGR

Animal studies suggest that phosphodiesterase-5 PDE5 inhibitors such as sildenafil citrate may improve uterine blood flow

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None